Skip to main content
MM logo
Daratumumab plus lenalidomide and dexamethasone showed deep clinical responses in patients who continued treatment for ≥18 months. Read More ›

Final results from the LYRA study demonstrate daratumumab plus cyclophosphamide, bortezomib, dexamethasone was well-tolerated and effective in patients with newly diagnosed or relapsed/refractory multiple myeloma. Read More ›

Better understanding of physician decision factors when selecting therapy for patients with refractory multiple myeloma may facilitate adoption of a wider variety of new treatment options. Read More ›

Subanalysis strongly supports the use of isatuximab plus carfilzomib and dexamethasone regardless of prior lines of therapy or refractory status to lenalidomide and bortezomib. Read More ›

Integrating a pharmacist into the care team can have substantial clinical and financial benefits in the setting of relapsed/refractory multiple myeloma and anti-CD38 antibodies. Read More ›

Carfilzomib plus dexamethasone and daratumumab show improved responses compared with carfilzomib plus dexamethasone in patients with relapsed/refractory multiple myeloma regardless of cytogenetic risk. Read More ›

The addition of autologous stem-cell transplantation to triplet induction—lenalidomide, bortezomib, and dexamethasone—plus lenalidomide maintenance until progression greatly improved progression-free survival. Read More ›

Patients with multiple myeloma require high levels of complex information regarding this complex disease and its treatments. Read More ›

Isatuximab added to carfilzomib and dexamethasone showed improved efficacy and safety versus carfilzomib and dexamethasone alone in East Asian patients with multiple myeloma. Read More ›

Page 3 of 5